Clinical Trials Logo

Filter by:
NCT ID: NCT03312530 Not yet recruiting - Multiple Myeloma Clinical Trials

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Start date: November 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This open-label, randomized, multicenter, triple-arm Phase Ib/II study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics of cobimetinib administered as a single agent (Arm A), cobimetinib plus venetoclax (Arm B), and cobimetinib plus venetoclax plus atezolizumab (Arm C) in participants with relapsed and refractory multiple myeloma. Two successive cohorts will evaluate the safety of cobimetinib plus venetoclax and that of cobimetinib plus venetoclax plus atezolizumab in the selected population during the safety run-in phase of the study. Once the dose levels have demonstrated acceptable safety during this phase, randomization will begin for all treatment arms (Arms A, B, and C).

NCT ID: NCT03311776 Recruiting - Pancreatic Cancer Clinical Trials

BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC")

BIOPAC
Start date: July 3, 2008
Phase: N/A
Study type: Observational

No validated biomarkers to identify PC at an early stage and to predict treatment outcomes in the individual patient exist. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.

NCT ID: NCT03311490 Not yet recruiting - Clinical trials for Athletes Who Have Incurred a Lateral Ankle Sprain in the Preceding 24 Months

The Spraino Pilot Trial

Start date: October 2017
Phase: N/A
Study type: Interventional

This pilot study will establish the preliminary effect and safety of using Spraino® to prevent lateral ankle sprains amongst athletes competing in indoor sports at sub-elite level, with a one-year follow-up. All recruited participants will have a history of lateral ankle sprain in the preceding 24 months prior to the initiation of the trial. Half of the included participants will receive Spraino® to prevent lateral ankle sprains (intervention group). The other half will receive no intervention ("do-as-usual" control group). Both groups will be permitted to continue or initiate any usual care of their choice, except Spraino® in the control group. Short Message Services (SMS) will be used for registration of injury and exposure.

NCT ID: NCT03310320 Not yet recruiting - Clinical trials for Plaque Psoriasis Vulgaris

This Study is Designed to See if AZD0284 is Effective in Treating Plaque Psoriasis and Whether it Causes Any Side Effects.

DERMIS
Start date: November 3, 2017
Phase: Phase 1
Study type: Interventional

The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. The severity of the disease varies, but in many cases it can have a major impact on their quality of life if not adequately treated. The purpose of the study is to determine the short term safety, pharmacodynamic and clinical effect of AZD0284 in patients with psoriasis.

NCT ID: NCT03310047 Not yet recruiting - Clinical trials for Anesthesia, Regional

Intra-individual Reproducibility in Nerve Block Duration

Start date: October 30, 2017
Phase: Phase 1
Study type: Interventional

An interventional randomized controlled crossover trial, to illuminate if durations in nerve block durations are predictable within the same subject.

NCT ID: NCT03309423 Recruiting - Sepsis Clinical Trials

Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU?

Start date: October 9, 2017
Phase: N/A
Study type: Observational

Objective: Arterial blood gas (ABG) is essential in the clinical assessment of potential acutely ill patients venous to arterial conversion (v-TAC), a mathematical method, has recently been developed to convert peripheral venous blood gas (VBG) values to arterialized VBG (aVBG) values. The aim of this study is to test the reliability of aVBG compared to ABG in an intensive care unit (ICU) setting. Method: Consecutive patients admitted to the ICU with pH values <7,35 or >7,45 are included in this study. Paired ABG and aVBG samples are drawn from patients via arterial catheter, central venous catheter and/or peripheral venous catheter and compared.

NCT ID: NCT03309215 Active, not recruiting - Clinical trials for Allergic Contact Dermatitis Due to Nickel

Short Repeated Nickel Exposures

Start date: September 16, 2017
Phase: N/A
Study type: Interventional

The former Nickel Directive was introduced in EU in 1994 limiting the release of nickel from items intended for prolonged contact with skin. The nickel regulation entered into full force in 2001 and became a part of REACH (the EU chemicals regulation) in 2009. Since then the prevalence of nickel allergy has declined in some countries, but not in others, following the implementation. Young individuals still become allergic to nickel (2, 3) and a high prevalence of nickel allergy, exceeding 10%, is seen among young women (below 30 years) in the general population. The EU nickel regulation has been changing over time. The present limits of nickel release for metallic items intended for direct and prolonged contact with the skin is <0.5 μg/cm2/week and <0.2 μg/cm2/week for any post assemblies inserted into pierced holes. In 2014, EU defined prolonged contact with the skin as: at least 30 minutes on one or more occasions within two weeks for items with continuous skin contact, or to at least 10 minutes on three or more occasions within two weeks (7). The overall objective is to evaluate how well the EU nickel regulation protects individuals against developing nickel dermatitis. More specifically we will: 1. Study the penetration of nickel in normal and irritated skin after short repeated skin exposure under controlled temperature in nickel sensitized patients and in healthy controls 2. Reveal the potential of short repeated nickel skin exposure on normal and irritated skin to elicit dermatitis, during controlled climate factors in nickel sensitized patients and controls using the time restrictions of the definition of prolonged skin contact in the nickel regulation.

NCT ID: NCT03308968 Not yet recruiting - Clinical trials for Migraine Prophylaxis

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

FOCUS
Start date: October 12, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in patients with chronic migraine (CM) or episodic migraine (EM) who have responded inadequately to 2 to 4 classes of prior preventive treatments. Approximately equal numbers of patients from each subgroup (CM and EM) are randomized in blinded-fashion 1:1:1 into one of three treatments for the subgroup - two active treatments and one placebo treatment --- consisting of monthly injections for 3 months (up to week 12). Then all participants continue into an open-label extension of 3 months (weeks 13-week 24) during which everyone is administered sc injections of fremanezumab.

NCT ID: NCT03308916 Recruiting - Fibrosis Clinical Trials

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

SIPHON
Start date: October 6, 2017
Phase: N/A
Study type: Interventional

Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.

NCT ID: NCT03307213 Not yet recruiting - Clinical trials for Coronary Artery Disease

BioFreedom QCA Study in CAD Patients

BioFreedomQCA
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

This study aims to demonstrate that the BioFreedom™ Cobalt Chromium Drug Coated Stent is non-inferior to the market authorized BioFreedom™ Stainless Steel Stent with respective to efficacy and shows a similar safety profile.